Strategic opportunities including specialty and biologics, alongside investment in innovation and launch, underline Japan’s position as the second-largest pharma market for R&D-driven pharma companies. Continued pressure on healthcare spending, however, is impacting both government policy and pharma company strategy as a balance emerges to support patient access to newer, safer and more effective treatments. While companies that made the shift in strategy reap their rewards, those that did not are now re-assessing their position.
At a ‘must’ event for the pharma industry, join us for a discussion of these and other issues impacting the Japan market today and in the years ahead with Alan Thomas, Director, Thought Leadership at IQVIA Japan K.K. John W. Carlson III, Chair William Bishop, Yuko Kidoguchi, Takeo Morooka, Toshio Nagase, R. Byron Sigel, Mika Shirai, Vice Chairs ACCJ Healthcare Committee Eiji Sasahara, Chair Eriko Asai, Marc Fuoti, Vice Chairs ACCJ Digital Health Subcommittee William Bishop, Chair Marie Kissel, Yasuhiko Amano, Jun Sekiguchi, Vice Chairs ACCJ Medical Devices and Diagnostics Subcommittee Takeo Morooka, Chair ACCJ Pharmaceuticals Subcommittee Yaju Hiromichi, Chair Satoshi Tanaka, Vice Chair ACCJ Regenerative Medicine and Bioscience Subcommittee NOTE 1: This event is OFF THE RECORD. NOTE 2: If you cancel after the stated deadline, the full meeting fee will be charged to your account. All guests must be accompanied by an ACCJ member. Sorry, no substitutions or walk-ins. NOTE 3: 500 yen of each participant's attendance fee will be deposited into the Healthcare Committee Fund. Comments are closed.
|
Details
If you need to cancel your registration due to illness, travel to affected areas within the past 14 days, or contact with someone who has traveled to affected areas, and the cancellation deadline has passed, please contact programs@accj.or.jp and accommodations will be made through March. For more details, please click here.
Events by Month
May 2020
Location
|